05/30/2026
Advancements in Canine Lymphoma Care: Tanovea and Laverdia Offer Novel Therapeutic Options for Dogs.
Tanovea and Laverdia are FDA-approved prescription medications indicated for the treatment of lymphoma in dogs, providing substantial extensions of remission in both treatment-naïve and relapsed cases, albeit with distinct administration routes and mechanisms of action.
Administration and Logistics Tanovea (rabacfosadine): This intravenous chemotherapy agent is administered by a veterinary oncologist or veterinarian via infusion once every three weeks, typically for a maximum of five doses. Laverdia (verdinexor): An oral tablet formulation administered twice weekly by the pet owner at home, with at least 72 hours between doses, often in conjunction with prednisone.
Mechanism of Action Tanovea: This targeted chemotherapy agent functions as a DNA synthesis inhibitor, selectively accumulating in rapidly dividing lymphoma cells and disrupting DNA replication, ultimately leading to cell death. Laverdia: A pioneering oral selective inhibitor of nuclear export (SINE), which sequesters proteins controlling tumor growth within the nucleus of cancer cells, thereby preventing cellular division and proliferation. Safety and Handling Given the potent antineoplastic properties of both medications, strict handling protocols are crucial for hospital staff and pet owners to minimize exposure.
Chemotherapy Precautions: Owners should wear chemotherapy-approved gloves when handling medication, feeding bowls, or cleaning up after their dog. Vulnerable Populations: Pregnant women, especially young nursing mothers, women of childbearing potential, and young children should avoid any contact with the medication or the dog's bodily fluids during treatment.
Selecting the Optimal Treatment Option
The choice between Tanovea and Laverdia depends on the specific lymphoma subtype, the dog's overall health status, cancer stage, and owner preferences. Tanovea is notable for inducing profound and durable remissions, although it carries a higher risk of adverse effects such as neutropenia and pulmonary complications. Laverdia offers a more manageable home administration regimen, albeit with stringent safety protocols. https://oncodaily.com/oncolibrary/dog-lymphoma-treatment.
Tanovea and Laverdia are FDA-approved treatment window.Which is right for your dog?Treatment choice depends on the specific type of lymphoma, the dog's overall health, the stage of the cancer, and owner preferences. Tanovea is known for delivering deep, durable remissions, but carries a higher risk of side effects like low white blood cell counts or lung-related issues. Laverdia is generally more manageable for home administration but requires rigorous at-home safety protocols.
